Wuxi Huatai Innovative Drug Technology Research Institute

Wuxi Huatai Innovative Drug Technology Research Institute is a biotechnology company and research organization focused on the development of innovative stem cell therapies and immunotherapies. Founded in 2018 by Professor Shi Yufang, a world-renowned immunologist and member of the European Academy of Sciences, the institute serves as a key biopharmaceutical innovation base in Wuxi, China. Its lead candidate, IHS002, is a human umbilical cord mesenchymal stem cell (hUC-MSC) product that has received IND approval and is currently in Phase 1 clinical trials for the treatment of chronic wounds, including burns, diabetic foot ulcers, and pressure sores. The company also maintains a pipeline of five additional stem cell-based programs targeting oncology, autoimmune diseases, and chronic organ injury. Wuxi Huatai operates the Jiangsu Stem Cell Technology Application Engineering Research Center and leverages its expertise in stem cell biology to develop 1.1 class innovative drugs. The institute is strategically located in the Wuxi Huishan Economic Development Zone, benefiting from a robust local life sciences ecosystem.